J&J’s IL-23 star guselkum­ab grabs the spot­light in PhI­II pso­ri­a­sis show­down

J&J has long had high hopes for its an­ti-in­flam­ma­to­ry IL-23 drug guselkum­ab. And to­day in Vi­en­na they de­tailed the first round of Phase III da­ta for se­vere plaque pso­ri­a­sis that ex­plains why.

In­ves­ti­ga­tors say this drug not on­ly hand­i­ly beat a place­bo, it al­so out­stripped the megablock­buster Hu­mi­ra in key mea­sures of ef­fi­ca­cy. And that will help po­si­tion the phar­ma gi­ant as it starts to line up reg­u­la­to­ry ap­provals for a new ther­a­py that’s like­ly head­ed in­to a heav­i­ly com­pet­i­tive mar­ket.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.